Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

OTHER 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 5Meningioma 3Prostatic Neoplasms 2Gastro-enteropancreatic neuroendocrine tumor 2Carcinoid Tumor 2Neuroblastoma 1Neoplasms 1Glioma 1Ganglioneuroma 1Ganglioneuroblastoma 1Disease 1Carcinoma, Medullary 1Breast Neoplasms 1Breast Cancer Metastatic 1Advanced Gastroenteropancreatic Neuroendocrine Tumor 1

Interventions

vandetanib 14cabozantinib 9selpercatinib 6Sorafenib 5Everolimus 5pralsetinib 3Magnetic Resonance Spectroscopy 3Capecitabine 3sargramostim 2lutetium Lu 177 dotatate 2lenvatinib 2Trastuzumab 2Thyroidectomy 2Temozolomide 2Sunitinib 2Specimen Handling 2Octreotide 2High-Energy Shock Waves 2Gefitinib 2Doxorubicin 2yeast-CEA vaccine 1veliparib 1vatalanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1temsirolimus 1tanespimycin 1sacubitril and valsartan sodium hydrate drug combination 1rovalpituzumab tesirine 1ponatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Medullary × Ga(III)-DOTATOC × Clear all
NCT02174679 2020-07-27

68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)

Jonsson Comprehensive Cancer Center

No longer available
EndocrineNET

Carcinoma, Medullary, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡